Vascular Changes Persist After Multisystem Inflammatory Syndrome in Children
18 Jan 2024
Clinical ResultAHA
THURSDAY, Jan. 18, 2024 -- Multisystem inflammatory syndrome in children (MIS-C) may be associated with an increased risk for future cardiovascular complications due to significant persistent vascular alterations, according to a research letter published online Jan. 16 in JAMA Pediatrics.
Julie Boever, from Ludwig Maximilian University of Munich, and colleagues conducted a case-control study of 17 patients with MIS-C and 17 matched controls with a median follow-up of 114.5 days.
The researchers found that during the acute phase, patients with MIS-C showed significantly damaged microcirculation, including lower median microvascular flow index (2.36 versus 2.80), total vessel density (16.14 versus 19.61 mm/mm2), and proportion of perfused vessels (12.31 versus 18.10 percent) compared with controls. There was alteration of vessel diameter distribution with significant capillary rarefication. Even without ongoing inflammation, impaired microcirculatory parameters persisted during follow-up. These findings persisted when adjusting for age, body mass index, and sex. In MIS-C, the augmentation index was significantly increased only during follow-up (median, −7.05 versus −18.01).
"This study emphasizes the importance of understanding the vascular impact of MIS-C during the acute phase and follow-up period to provide appropriate medical care and interventions," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.